Mazdutide vs Retatrutide
A side-by-side research comparison of Mazdutide and Retatrutide across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Mazdutide | Retatrutide |
|---|---|---|
| Full name | Mazdutide (Dual GLP-1/Glucagon Agonist) | Retatrutide (Triple Agonist GIP/GLP-1/Glucagon) |
| Category | Weight Management | Weight Management |
| Status | Phase 3 Clinical Trial | Phase 3 Clinical Trial |
| Mechanism | Dual activation of GLP-1 receptors for appetite suppression combined with glucagon receptor activation for enhanced hepatic lipid oxidation and energy expenditure. | Triple agonism creates synergistic metabolic effects. Glucagon activation increases energy expenditure and hepatic fat oxidation while GLP-1/GIP reduce appetite and improve insulin sensitivity. |
| Molecular weight | 4,300 Da (approximate) | 5,200 Da (approximate) |
| Half-life | 5-7 days | 6 days |
| Bioavailability | High (SubQ) | High (SubQ) |
| Typical dose | 3-9 mg | 1-2 mg → titrate up to 12 mg |
| Frequency | Once weekly | Once weekly |
| Route | Subcutaneous | Subcutaneous injection |
Mazdutide reported benefits
- Significant weight loss (up to 18%)
- Liver fat reduction
- Improved insulin sensitivity
- Once-weekly convenience
- Potential MASH benefit
Retatrutide reported benefits
- Unprecedented weight loss (~24%)
- Significant liver fat reduction
- Improved cardiovascular markers
- Enhanced energy expenditure
- Superior glycemic control
Related comparisons
Research and educational reference only. Not medical advice.